79 related articles for article (PubMed ID: 24623744)
1. An update on Mullerian-inhibiting substance: its potential application against ovarian cancer.
Wong RR; Worley MJ; Chung TK; Wong YF
Endocr Relat Cancer; 2014 Jun; 21(3):R227-33. PubMed ID: 24623744
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
[TBL] [Abstract][Full Text] [Related]
3. Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo.
Stephen AE; Pearsall LA; Christian BP; Donahoe PK; Vacanti JP; MacLaughlin DT
Clin Cancer Res; 2002 Aug; 8(8):2640-6. PubMed ID: 12171896
[TBL] [Abstract][Full Text] [Related]
4. AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.
Pépin D; Sosulski A; Zhang L; Wang D; Vathipadiekal V; Hendren K; Coletti CM; Yu A; Castro CM; Birrer MJ; Gao G; Donahoe PK
Proc Natl Acad Sci U S A; 2015 Aug; 112(32):E4418-27. PubMed ID: 26216943
[TBL] [Abstract][Full Text] [Related]
5. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
6. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
Pieretti-Vanmarcke R; Donahoe PK; Pearsall LA; Dinulescu DM; Connolly DC; Halpern EF; Seiden MV; MacLaughlin DT
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17426-31. PubMed ID: 17088539
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic effects of müllerian inhibiting substance (MIS)?
Janssens JP; Noto V; van Tendeloo G; Bonte J; de Loecker W
Anticancer Res; 1988; 8(4):781-4. PubMed ID: 3178166
[TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness.
Szotek PP; Pieretti-Vanmarcke R; Masiakos PT; Dinulescu DM; Connolly D; Foster R; Dombkowski D; Preffer F; Maclaughlin DT; Donahoe PK
Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11154-9. PubMed ID: 16849428
[TBL] [Abstract][Full Text] [Related]
9. Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.
Wallen JW; Cate RL; Kiefer DM; Riemen MW; Martinez D; Hoffman RM; Donahoe PK; Von Hoff DD; Pepinsky B; Oliff A
Cancer Res; 1989 Apr; 49(8):2005-11. PubMed ID: 2702642
[TBL] [Abstract][Full Text] [Related]
10. Müllerian inhibiting substance in reproduction and cancer.
Donahoe PK
Mol Reprod Dev; 1992 Jun; 32(2):168-72. PubMed ID: 1637555
[TBL] [Abstract][Full Text] [Related]
11. Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance.
Seifer DB; Maclaughlin DT
Fertil Steril; 2007 Sep; 88(3):539-46. PubMed ID: 17559842
[TBL] [Abstract][Full Text] [Related]
12. Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.
MacLaughlin DT; Donahoe PK
Future Oncol; 2010 Mar; 6(3):391-405. PubMed ID: 20222796
[TBL] [Abstract][Full Text] [Related]
13. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.
Zhan Y; Fujino A; MacLaughlin DT; Manganaro TF; Szotek PP; Arango NA; Teixeira J; Donahoe PK
Development; 2006 Jun; 133(12):2359-69. PubMed ID: 16687449
[TBL] [Abstract][Full Text] [Related]
14. Müllerian inhibiting substance/anti-Müllerian hormone as a fertility preservation agent.
Pépin D; Sabatini ME; Donahoe PK
Curr Opin Endocrinol Diabetes Obes; 2018 Dec; 25(6):399-405. PubMed ID: 30320617
[TBL] [Abstract][Full Text] [Related]
15. Autocrine and paracrine Müllerian inhibiting substance hormone signaling in reproduction.
Ingraham HA; Hirokawa Y; Roberts LM; Mellon SH; McGee E; Nachtigal MW; Visser JA
Recent Prog Horm Res; 2000; 55():53-67; discussion 67-8. PubMed ID: 11036933
[TBL] [Abstract][Full Text] [Related]
16. The Anti-Mullerian hormone and ovarian cancer.
La Marca A; Volpe A
Hum Reprod Update; 2007; 13(3):265-73. PubMed ID: 17213257
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of Müllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors.
Lane AH; Lee MM; Fuller AF; Kehas DJ; Donahoe PK; MacLaughlin DT
Gynecol Oncol; 1999 Apr; 73(1):51-5. PubMed ID: 10094880
[TBL] [Abstract][Full Text] [Related]
18. Mullerian-inhibiting substance secretion is delayed in XX sex-reversed dog embryos.
Meyers-Wallen VN; MacLaughlin D; Palmer V; Donahoe PK
Mol Reprod Dev; 1994 Sep; 39(1):1-7. PubMed ID: 7999353
[TBL] [Abstract][Full Text] [Related]
19. Abnormal sexual development in transgenic mice chronically expressing müllerian inhibiting substance.
Behringer RR; Cate RL; Froelick GJ; Palmiter RD; Brinster RL
Nature; 1990 May; 345(6271):167-70. PubMed ID: 2336108
[TBL] [Abstract][Full Text] [Related]
20. Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines.
Chang HL; Pieretti-Vanmarcke R; Nicolaou F; Li X; Wei X; MacLaughlin DT; Donahoe PK
Gynecol Oncol; 2011 Jan; 120(1):128-34. PubMed ID: 21056908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
